3 US Generics Exporter, Anti-Infectives Franchise Owner and Biggest Indian Drug Maker by Value Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma
- October 29, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma: ROE of 11.9% to 16.7% and FY22 to FY26 revenue CAGR of 8.4% to 11.6%. Prices as of 27 Oct 2026.
Quick Answer
The three generics, anti-infective and pharma leader to watch are Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma. Their return on equity ranges from 11.9% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 11.6%. Alkem Laboratories has the highest return on equity at 16.7%, while Sun Pharma has the fastest revenue growth at 11.6% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Generics, anti-infective and pharma leader give investors a way to track businesses that sit close to everyday demand in India. Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma cover a generics and branded formulations company, an anti-infectives and chronic therapy leader and the largest Indian pharma group.
This list covers three generics, anti-infective and pharma leader with complete current figures: Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generics, Anti-infective and Pharma Leader?
Generics, anti-infective and pharma leader are listed pharmaceutical companies that sell generic formulations in the United States and branded medicines in India, lead in anti-infectives and gastro-intestinal therapies and run branded, generics and specialty businesses. Their earnings depend on launches, approvals and brand strength.
Generics, Anti-infective and Pharma Leader at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals | 782.8 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
| Alkem Laboratories | 5,070 | 59,723 | 27.1 | 36.0 | 16.7 | 0.15 |
| Sun Pharma | 1,757.5 | 422,283 | 34.9 | 36.2 | 13.7 | 0.06 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing generics, anti-infective and pharma leader should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Generics, Anti-infective and Pharma Leader Have a Strong Roadmap in India?
Generics, anti-infective and pharma leader have a strong roadmap in India because rising healthcare spending, steady domestic prescription demand and new launches keep widening the market for Indian pharmaceutical firms.
- Domestic prescriptions. Anti-infectives and chronic care see steady use.
- Export launches. Approvals open regulated markets.
- Specialty growth. New brands broaden the product mix.
Why Alembic Pharmaceuticals Features Among These Generics, Anti-infective and Pharma Leader
Among the generics, anti-infective and pharma leader on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Why Alkem Laboratories Features Among These Generics, Anti-infective and Pharma Leader
Among the US generics, domestic anti-infectives and specialty shares on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.
Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%.
In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.
Roadmap: Alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.
Why Sun Pharma Features Among These Generics, Anti-infective and Pharma Leader
Among the three companies on this list, Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.
In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%.
Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.
Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What to watch: Track specialty product launches, United States approvals and domestic prescription trends.
Alembic Pharmaceuticals vs Alkem Laboratories vs Sun Pharma on Key Financials
The table below sets the three generics, anti-infective and pharma leader side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
| Alkem Laboratories | 10,797 | 15,296 | 9.1% | 2,353 | 15.4% |
| Sun Pharma | 39,730 | 61,674 | 11.6% | 11,565 | 18.8% |
Alkem Laboratories posts the highest return on equity in this group at 16.7%. Sun Pharma combines the largest FY26 revenue at Rs 61,674 crore with the fastest revenue growth, a 11.6% compound annual rate. A useful habit with generics, anti-infective and pharma leader is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Alembic Pharmaceuticals | 1,717 | 2,165 | 26.1% |
| Alkem Laboratories | 3,508 | 3,893 | 11.0% |
| Sun Pharma | 14,316 | 16,024 | 11.9% |
Key Risks to Check Before Investing in Generics, Anti-infective and Pharma Leader
Every theme carries risks that deserve a check before any decision. For these generics, anti-infective and pharma leader, the main points are: Long-term US generics, domestic anti-infectives and specialty shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter generics, anti-infective and pharma leader by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Generics, Anti-infective and Pharma Leader
Generics, anti-infective and pharma leader work best when investors track growth, valuation and return on equity side by side. Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma each have a clear plan to expand. Based on the 27 October 2026 close, Alembic Pharmaceuticals trades at Rs 782.8, Alkem Laboratories at Rs 5,070 and Sun Pharma at Rs 1,757.5. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these generics, anti-infective and pharma leader to a watchlist.
Download the Univest iOS App or Univest Android App to track generics, anti-infective and pharma leader, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are generics, anti-infective and pharma leader?
Ans. Generics, anti-infective and pharma leader are listed pharmaceutical companies that sell generic formulations in the United States and branded medicines in India, lead in anti-infectives and gastro-intestinal therapies and run branded, generics and specialty businesses. Their earnings depend on launches, approvals and brand strength. This list looks at three of them, Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which generics, anti-infective and pharma leader are covered in this list?
Ans. This list covers Alembic Pharmaceuticals, Alkem Laboratories and Sun Pharma. Based on the 27 October 2026 close, Alembic Pharmaceuticals traded at Rs 782.8, Alkem Laboratories at Rs 5,070 and Sun Pharma at Rs 1,757.5. Their return on equity ranges from 11.9% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 11.6%.
Why do generics, anti-infective and pharma leader have a strong future roadmap in India?
Ans. Generics, anti-infective and pharma leader have a strong roadmap in India because rising healthcare spending, steady domestic prescription demand and new launches keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Domestic prescriptions. Anti-infectives and chronic care see steady use. Export launches. Approvals open regulated markets. Specialty growth. New brands broaden the product mix. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
How has Alkem Laboratories performed financially?
Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
How has Sun Pharma performed financially?
Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What risks should investors check before buying generics, anti-infective and pharma leader?
Ans. Investors should check a few risks before buying generics, anti-infective and pharma leader. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of generics, anti-infective and pharma leader investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
